Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

A conversation with Debra Dullinger, PharmD.

¹Pharmacy Gold, Inc., St. Paul, MN.

Medical Interface

|September 5, 1994

Summary

This summary is machine-generated.

Pharmacy benefit managers (PBMs) are adapting to healthcare reform. This expert offers insights into the evolving PBM landscape and its interactions with pharmaceutical companies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Efficacy of inhaled metaproterenol and orally-administered theophylline in patients with chronic airflow obstruction.

Chest·1986

See all related articles

Area of Science:

Health Policy
Pharmacy Management

Background:

The healthcare landscape is undergoing significant reform.
Pharmacy benefit management (PBM) companies play a crucial role in managing drug benefits.
Recent activity between PBMs and pharmaceutical companies warrants examination.

Discussion:

The current environment is characterized by significant activity between PBMs and pharmaceutical companies.
The Journal sought Dr. Dullinger's expert opinion on these dynamics and their implications.

Key Insights:

PBMs play a crucial role in the managed care pharmacy sector.
Understanding PBM-pharmaceutical company interactions is key to navigating the current healthcare environment.

Outlook:

Related Experiment Videos

The role of PBMs is undergoing transformation due to ongoing health reform initiatives.

Future strategies will likely be shaped by the interplay between PBMs, pharmaceutical companies, and regulatory changes.